COMP <GO>
IOVA vs ADPT // RETURN ON INVESTED CAPITAL (ROIC)
Iovance Biotherapeutics Inc. (NASDAQ) VS. Adaptive Biotechnologies Corporation (NASDAQ) • 15-METRIC TALLY: IOVA 2
— ADPT 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ADPT
LAST: $9.56 (-35.45%) • MKT CAP: $4.33B
roic
-35.00%
LAST: $28.17 (-0.70%) • MKT CAP: $4.50B
roic
-12.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IOVA VS. ADPT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IOVA | ADPT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 34.30% | 74.20% | -39.90 | ADPT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | -12.50% | -22.50 | ADPT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.76% | -1.09% | -6.67 | ADPT | /fcf-yield <GO> |
| Operating Margin | -60.00% | -20.60% | -39.40 | ADPT | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -21.50% | -38.50 | ADPT | /net-margins <GO> |
| Revenue Growth (YoY) | 60.60% | 54.80% | +5.80 | IOVA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.08 | 6.32 | +0.76 | IOVA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 6/9 | -2.00 | ADPT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.8 | 57.6 | -20.80 | ADPT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 1.01 | -0.02 | ADPT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 26.0x | +7.00 | ADPT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.33B | $4.50B | -$165.4M | ADPT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IOVA REV | ADPT REV | IOVA GROSS % | ADPT GROSS % | IOVA FCF | ADPT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $263.5M | $277.0M | 34.3% | 74.2% | -$336.2M | -$48.9M |
| FY 2024 | $164.1M | $179.0M | 43.2% | 59.7% | -$364.0M | -$98.9M |
| FY 2023 | $1.2M | $170.3M | — | — | -$361.9M | -$164.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IOVA // BETA 0.99
ADPT // BETA 1.01